Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction to absorb

This article was originally published in The Tan Sheet

Executive Summary

The online retailer will acquire owner Salu Inc. for $36 million and move "one step closer toward achieving our goal of becoming the leading online retailer of beauty and spa products," says. The Bellevue, Wash.-based firm on Dec. 28 said it intends to close the half-cash, half-stock deal in the first quarter of 2010., which carries skin health supplements, sun care products and clinical skin care items, will complement the higher-end cosmetics in the portal, which acquired in 2000 (1"The Tan Sheet" May 1, 2000). Salu, which will continue to operate in Sacramento, Calif., is expected to generate $40 million in revenue and $500,000 in net income for 2009

You may also be interested in... Traffic Up 20-30% Since Partnership - Neupert's strategic partnership with has increased site traffic 20%-30% since the launch of a "Health & Beauty" tab linking the two sites, Chairman and CEO Peter Neupert reported in an April 24 call with securities analysts.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts